Arcosa Inc

ACA remains in a Stage 2 advancing uptrend with active Lockout Rally continuation driving price above rising EMAs. Despite overbought context, a recent pullback into the 9 EMA and 21 EMA region offers a tactical entry aligned with momentum-driven participation. We recommend Buy Now to engage the medium-term bullish trend under confirmed institutional demand dynamics.

• ↑Q4 2025 revenue $2.9B (+12% YoY) and adjusted EBITDA $583M (+30%).
• ↑Adjusted EBITDA margin reached 20.2%, driven by efficiency gains.
• ↓Negative profitability factors point to margin headwinds ahead.